No Data
No Data
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $47
Barclays analyst Luke Sergott maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $47.According to TipRanks data, the analyst has a success rate of 42.3% and a total av
Ardena Appoints Jeremie Trochu as Chief Executive Officer
Ardena (the "Company") today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive...
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Topline Readout Expected in Q4 2024NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation,
Express News | NYSE Order Imbalance 740863.0 Shares on Sell Side
Catalent (NYSE:CTLT) Investors Are Sitting on a Loss of 47% If They Invested Three Years Ago
As an investor its worth striving to ensure your overall portfolio beats the market average.
Is Catalent (NYSE:CTLT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.'